Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.
QNTM · Quantum Biopharma Ltd.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.42
- Open
- $1.55
- Day range
- $1.38–1.64
- 52-week closing range
- $1.42–11.41
- Average volume, 30 days
- 109K
- Short interest
- 440K · 6.8% of shares · 4.5 days
- Short volume, last session
- 47%
- Price history
- Jan 2020 to Nov 2026
Latest documents
Quantum Biopharma Ltd. reported a nine-month net loss of 17,320,779, down from 23,253,808, while period-end cash reached 3,556,345 and digital assets totaled 8,658,775.
Quantum BioPharma raised C$80.86 by privately placing 26 Class A Multiple Voting Shares on November 9, 2026, lifting voting power to approximately 68.22%. Shareholders authorized consolidation of up to ten (10) pre-consolidation shares for one (1) post-consolidation share.
Quantum BioPharma Ltd. corrected fractional-share rounding for its proposed consolidation and clarified that the 70% cap on MVS holders’ voting power applies only if Class B Subordinate Voting Share cancellations would raise their aggregate voting power above 70%.
Quantum BioPharma Ltd. announced that the United States District Court for the Southern District of New York consolidated its direct action and an investor-led class action alleging market manipulation, appointing Grant & Eisenhofer P.A. as lead counsel.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QNTM
this stock
Quantum Biopharma Ltd.
|
$9.13M | -80.5% | — | — | 6.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 31
Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QNTM | -20.2% | -37.4% | -73.0% | -40.3% | -80.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -14.8% | -31.2% | -67.3% | -35.1% | -85.5% |